Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just a thought

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Apr 22, 2021 9:49am

127 Views

Post# 33043873

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Just a thought

Yes, I thought this was one of the better conferences too. It almost seemed like the moderator knew the questions to ask and Dan was able to provide some good answers. I imagine some of those questions were prepped which was probably a good thing.

Couple thoughts/critiques though.

Man, I wish they should shelf the whole "wake up in the ICU with 3 pints of blood" when talking about ulceration for Naproxen. It sounds a bit hyperbolic even if it may be true. Just state that this could lead to hospitalization and leave it at that. Most of the time I find the statements to be underwelming but I feel like this one is a little too over the top.

I loved that they spoke to cost per day for production and expected sale price. The more we can speak to how much we may get in royalties from partnership vs. ongoing cost I think is a strong point for ATE. They have a small staff base so any discussion around overhead I think is a benefit. I know its in their filings but a quickly highlight of that would help sell how much profit this company stands to make when projecting out their commecial prospects.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project